Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026827 (
hypotonia
)
5,860
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recently
WAC
was reported as a candidate gene for intellectual disability (ID) based on the identification of a de novo mutation in an individual with severe ID.
WAC
regulates transcription-coupled histone H2B ubiquitination and has previously been implicated in the 10p12p11 contiguous gene deletion syndrome. In this study, we report on 10 individuals with de novo
WAC
mutations which we identified through routine (diagnostic) exome sequencing and targeted resequencing of
WAC
in 2326 individuals with unexplained ID. All but one mutation was expected to lead to a loss-of-function of
WAC
. Clinical evaluation of all individuals revealed phenotypic overlap for mild ID,
hypotonia
, behavioral problems and distinctive facial dysmorphisms, including a square-shaped face, deep set eyes, long palpebral fissures, and a broad mouth and chin. These clinical features were also previously reported in individuals with 10p12p11 microdeletion syndrome. To investigate the role of
WAC
in ID, we studied the importance of the Drosophila
WAC
orthologue (CG8949) in habituation, a non-associative learning paradigm. Neuronal knockdown of Drosophila CG8949 resulted in impaired learning, suggesting that
WAC
is required in neurons for normal cognitive performance. In conclusion, we defined a clinically recognizable ID syndrome, caused by de novo loss-of-function mutations in
WAC
. Independent functional evidence in Drosophila further supported the role of
WAC
in ID. On the basis of our data
WAC
can be added to the list of ID genes with a role in transcription regulation through histone modification.
...
PMID:De novo loss-of-function mutations in WAC cause a recognizable intellectual disability syndrome and learning deficits in Drosophila. 2675 81
Pathogenic variants in
WAC
are uncommon causes of developmental delay and neurobehavioral phenotypes. The clinical features associated with
WAC
haploinsufficiency include recognizable dysmorphic facial features that were recently delineated as DeSanto-Shinawi syndrome (DESSH; OMIM 616708). Additional clinical features include
hypotonia
, hearing and vision abnormalities, gastrointestinal problems, and behavioral difficulties. Here, we report a case of a 4-year-old Colombian male patient with typical dysmorphic facial features, developmental delay, hyperactivity, and recurrent respiratory infections. His immune workup revealed hypogammaglobulinemia, and clinical exome sequencing revealed a novel intronic variant in
WAC
(c.1437+1G>A). To the best of our knowledge, this is the first case of DESSH in South America, underlining the accumulating evidence of the significant role of
WAC
haploinsufficiency in neurobehavioral phenotypes. Although this report suggested the potential involvement of
WAC
in immune regulation, additional reports are required to confirm our observations.
...
PMID:DeSanto-Shinawi Syndrome: First Case in South America. 2992 81
WAC
(WW Domain Containing Adaptor With Coiled-Coil) mutations have been reported in only 20 individuals presenting a neurodevelopmental disorder characterized by intellectual disability, neonatal
hypotonia
, behavioral problems, and mildly dysmorphic features. Using targeted deep sequencing, we screened a cohort of 630 individuals with variable degrees of intellectual disability and identified five
WAC
rare variants: two variants were inherited from healthy parents; two previously reported de novo mutations, c.1661_1664del (p.Ser554*) and c.374C>A (p.Ser125*); and a novel c.381+2T>C variant causing the skipping of exon 4 of the gene, inherited from a reportedly asymptomatic father with somatic mosaicism. A phenotypic evaluation of this individual evidenced areas of cognitive and behavioral deficits. The patient carrying the novel splicing mutation had a clinical history of encephalopathy related to status epilepticus during slow sleep (ESES), recently reported in another
WAC
individual. This first report of a
WAC
somatic mosaic remarks the contribution of mosaicism in the etiology of neurodevelopmental and neuropsychiatric disorders. We summarized the clinical data of reported individuals with
WAC
pathogenic mutations, which together with our findings, allowed for the expansion of the phenotypic spectrum of
WAC
-related disorders.
...
PMID:A Novel WAC Loss of Function Mutation in an Individual Presenting with Encephalopathy Related to Status Epilepticus during Sleep (ESES). 3221 4